专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150141452A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS 审中-公开
标题翻译：影响重量损失的组合物
公开(公告)号：US20150141452A1
公开(公告)日：2015-05-21
申请号：US14602154
申请日：2015-01-21
申请人： Orexigen Therapeutics, Inc.
发明人： Eckard Weber , Michael Alexander Cowley
IPC分类号： A61K31/485 , A61K31/135 , A61K31/137 , A61K31/138
CPC分类号： A61K31/485 , A61K31/135 , A61K31/137 , A61K31/138 , A61K45/06 , A61P3/04 , Y10S514/909 , Y10S514/964 , A61K2300/00
摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
摘要翻译：公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是阿片样物质拮抗剂，第二化合物引起黑皮质素3受体（MC3-R）或黑皮质素4受体（MC4-R））与正常生理条件相比。还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，包括鉴定有需要的个体并治疗该个体以拮抗阿片受体活性和增强α-MSH活性。

2. 发明申请

US20140287037A1 EXTENDED-RELEASE TOPIRAMATE CAPSULES 有权
公开(公告)号：US20140287037A1
公开(公告)日：2014-09-25
申请号：US14157646
申请日：2014-01-17
申请人： Upsher-Smith Laboratories, Inc.
发明人： Sarah Michelle Betterman , Jaidev Srinivas Tantry , Laura Marie Patrick
IPC分类号： A61K9/48 , A61K31/357
CPC分类号： A61K9/50 , A61K9/16 , A61K9/28 , A61K9/2866 , A61K9/4891 , A61K9/5047 , A61K31/357 , A61K31/7048 , C07D311/02 , C07D493/12 , C07D493/14 , Y10S514/963 , Y10S514/964
摘要： An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

3. 发明申请

US20140135529A1 METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT 审中-公开
标题翻译：将NMDA受体拮抗剂施用于受试者的方法
公开(公告)号：US20140135529A1
公开(公告)日：2014-05-15
申请号：US14081643
申请日：2013-11-15
申请人： ADAMAS PHARMACEUTICALS, INC.
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K31/13
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine xconcentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
摘要翻译：提供了向受试者施用美金刚的组合物和方法。特别地，提供了一次每日口服给药的单位剂型的固体药物组合物。组合物包含22.5mg至33.75mg美金刚或其药学上可接受的盐的延长释放制剂，其中向人受试者施用一定剂量的组合物提供了以美金刚x浓度变化为特征的平均血浆美金刚浓度分布时间的函数（dC / dT）小于在美金刚给药后0小时至6小时之间的时间段内由相同量的美金刚立即释放形式提供的dC / dT的50％，其中在单次剂量人体PK研究中测量dC / dT。提供了使用该组合物治疗痴呆，特别是阿尔茨海默氏病的方法。

4. 发明申请

US20110059169A1 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject 审中-公开
标题翻译：用于管理受试者的NMDA受体拮抗剂的方法和组合物
公开(公告)号：US20110059169A1
公开(公告)日：2011-03-10
申请号：US12840132
申请日：2010-07-20
申请人： Gregory T. Went , Timothy J. Fuitz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
发明人： Gregory T. Went , Timothy J. Fuitz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K31/13 , A61K9/00 , A61K9/22 , A61K9/24 , A61K9/52 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
摘要翻译：本发明提供了用于向受试者施用NMDA受体拮抗剂（例如美金刚）的方法和组合物。

5. 发明申请

US20100266684A1 METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT 审中-公开
标题翻译：将NMDA受体拮抗剂用于对象的方法和组合物
公开(公告)号：US20100266684A1
公开(公告)日：2010-10-21
申请号：US12757824
申请日：2010-04-09
申请人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
发明人： Gregory T. Went , Timothy J. Fultz , Seth Porter , Laurence R. Meyerson , Timothy S. Burkoth
IPC分类号： A61K9/52 , A61K31/13 , A61K9/14 , A61K31/445 , A61P25/28 , A61P25/02
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
摘要翻译：本发明提供了用于向受试者施用NMDA受体拮抗剂（例如美金刚）的方法和组合物。

6. 发明申请

US20100196478A1 PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF 有权
标题翻译：蛋白质基质材料，其制备方法及其使用方法
公开(公告)号：US20100196478A1
公开(公告)日：2010-08-05
申请号：US12700896
申请日：2010-02-05
申请人： David B. MASTERS
发明人： David B. MASTERS
IPC分类号： A61K9/10 , A61K38/16 , A61K35/00 , A61K38/43 , A61P17/02 , A61P43/00
CPC分类号： A61K9/0024 , A61K9/0085 , A61K9/7007 , A61K47/42 , A61L27/227 , A61L27/54 , A61L31/10 , A61L31/16 , A61L2300/602 , A61L2300/606 , A61L2300/622 , Y10S514/95 , Y10S514/953 , Y10S514/955 , Y10S514/964 , Y10S623/915 , C08L89/00
摘要： The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.
摘要翻译：本发明涉及蛋白质基质材料和装置，以及制备和使用蛋白质基质材料和装置的方法。更具体地，本发明涉及可用于各种医学应用的蛋白质基质材料和装置，包括但不限于用于药理学活性剂的控制释放的药物递送装置，包封的或涂覆的支架装置，血管，管状移植物，血管移植物，伤口愈合装置，包括蛋白质基质缝合材料和网眼，皮肤/骨/组织移植物，生物相容导电基质，透明蛋白质基质，蛋白质基质粘附防止屏障，细胞支架和其他生物相容性蛋白质基质装置。此外，本发明涉及通过形成包含一种或多种可生物降解的蛋白质材料，一种或多种生物相容性溶剂和任选的一种或多种药理学活性剂的膜制备的蛋白质基质材料和装置。然后将膜部分干燥，滚动或以其他方式成形，然后压缩以形成所需的蛋白质基质装置。

7. 发明申请

US20100190793A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS 审中-公开
标题翻译：影响重量损失的组合物
公开(公告)号：US20100190793A1
公开(公告)日：2010-07-29
申请号：US12751970
申请日：2010-03-31
申请人： Eckard Weber , Michael Alexander Cowley
发明人： Eckard Weber , Michael Alexander Cowley
IPC分类号： A61K31/485 , A61K31/451 , A61K31/135 , A61K31/5375 , A61P3/00
CPC分类号： A61K31/485 , A61K31/135 , A61K31/137 , A61K31/138 , A61K45/06 , A61P3/04 , Y10S514/909 , Y10S514/964 , A61K2300/00
摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
摘要翻译：公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是阿片样物质拮抗剂，第二化合物引起黑皮质素3受体（MC3-R）或黑皮质素4受体（MC4-R））与正常生理条件相比。还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，包括鉴定有需要的个体并治疗该个体以拮抗阿片受体活性和增强α-MSH活性。

8. 发明授权

US07709022B2 Sustained-release preparations of quinolone antibiotics and method for preparation thereof 有权
标题翻译：喹诺酮类抗生素缓释制剂及其制备方法
公开(公告)号：US07709022B2
公开(公告)日：2010-05-04
申请号：US10311913
申请日：2001-06-13
申请人： Venkata-Rangarao Kanikanti , Roland Rupp , Wolfgang Weber , Peter Deuringer , Jan-Olav Henck , Heino Staβ , Takaaki Nishioka , Yoshifumi Katakawa , Chika Taniguchi , Hitoshi Ichihashi
发明人： Venkata-Rangarao Kanikanti , Roland Rupp , Wolfgang Weber , Peter Deuringer , Jan-Olav Henck , Heino Staβ , Takaaki Nishioka , Yoshifumi Katakawa , Chika Taniguchi , Hitoshi Ichihashi
IPC分类号： A61K9/20 , A61K9/14 , A61K31/47
CPC分类号： A61K31/496 , A61K9/2027 , A61K9/2054 , A61K9/209 , A61K31/47 , A61K31/495 , C07D401/04 , Y10S514/96 , Y10S514/964 , A61K2300/00
摘要： The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
摘要翻译：本发明涉及可延缓释放活性化合物的喹诺酮抗生素的可口服制剂。

9. 发明授权

US07619007B2 Method and composition for administering an NMDA receptor antagonist to a subject 有权
标题翻译：用于给受试者施用NMDA受体拮抗剂的方法和组合物
公开(公告)号：US07619007B2
公开(公告)日：2009-11-17
申请号：US11285905
申请日：2005-11-22
申请人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K31/16 , A61K31/04 , A61K9/22 , A01N33/18 , A01N33/24
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
摘要翻译：本发明提供了用于向受试者施用NMDA受体拮抗剂（例如美金刚）的方法和组合物。

10. 发明授权

US07547452B2 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles 失效
标题翻译：微胶囊化的3-哌啶基取代的1,2-苯并异恶唑和1,2-苯并异噻唑
公开(公告)号：US07547452B2
公开(公告)日：2009-06-16
申请号：US11826384
申请日：2007-07-13
申请人： Thomas J. Atkins , Michael E. Rickey , Jean Mesens
发明人： Thomas J. Atkins , Michael E. Rickey , Jean Mesens
IPC分类号： A61K9/52 , A61K9/50 , A61K31/519
CPC分类号： A61K9/0024 , A61K9/1647 , A61K31/505 , A61K31/517 , A61K31/519 , Y10S514/962 , Y10S514/963 , Y10S514/964 , Y10S514/965
摘要： Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
摘要翻译：缓释微粒组合物。可以配制微粒组合物以在约7天至约200天的时间段内提供延长的释放。微粒可与生物可降解和生物相容的聚合物和活性剂如利培酮，9-羟基 - 利培酮和上述药学上可接受的酸加成盐一起配制。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式